cytoreduction surgical procedures


Summary: Operative procedures carried out to reduce a mass of tissue, for example, to reduce the total amount of tissue composing a tumor.

Top Publications

  1. Mehta A, Mittal R, Chandrakumaran K, Carr N, Dayal S, Mohamed F, et al. Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Dis Colon Rectum. 2017;60:1155-1161 pubmed publisher
    ..For these reasons, we adopted a policy of prophylactic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy...
  2. Saxena A, Valle S, Liauw W, Morris D. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma. Anticancer Res. 2017;37:5737-5742 pubmed
    ..Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a promising treatment option. We evaluated our experience of CRS-HIPEC for the treatment of SBA...
  3. Melamed A, Nitecki R, Boruta D, del Carmen M, Clark R, Growdon W, et al. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstet Gynecol. 2017;129:861-869 pubmed publisher
    ..Laparoscopy is associated with a modestly shorter postoperative hospitalization, whereas readmission rates and risk of perioperative death are similar for the surgeries. ..
  4. Bacalbasa N, Balescu I, Filipescu A. Debulking Surgery for Clear Cell Carcinoma of the Ovary - A Case Report and Literature Review. Anticancer Res. 2017;37:5707-5711 pubmed
    ..The histopathological studies demonstrated the presence of a well-differentiated clear cell ovarian carcinoma of the ovary. At 1-year follow-up there is no evidence of residual disease...
  5. Gabriel E, Singla S, Kim M, Fisher D, Powers C, Visioni A, et al. Water lavage as an adjunct to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Am J Surg. 2017;214:462-467 pubmed publisher
    ..32 vs WL-:0.39, p = 0.47). A subset analysis for patients with PCI >20 showed no difference between groups. WL offers a low cost, safe and theoretically efficacious method of tumor cell lysis for peritoneal malignancy. ..
  6. CRIM A, Rowland M, Ruskin R, Dvorak J, Greenwade M, Walter A, et al. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017;146:268-272 pubmed publisher
    ..IP CT appears well tolerated and effective among select older patients and is likely under-utilized outside of clinical trials. ..
  7. Hsieh M, Lu C, Chang W, Wu S, Hsiao P, Liu T. Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan. Medicine (Baltimore). 2017;96:e7306 pubmed publisher
    ..We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases. ..
  8. Shiralkar S, Kerr P, Scott J, Sivalingam P. Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit. Anaesth Intensive Care. 2017;45:490-498 pubmed
    ..Further research is required to evaluate the effects of intraoperative tranexamic acid and different intraoperative fluid strategies on outcomes in patients undergoing CRS with HIPEC. ..
  9. Eoh K, Yoon J, Lee I, Lee J, Kim S, Kim S, et al. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. J Surg Oncol. 2017;116:329-336 pubmed publisher
    ..Multivariate analysis identified LND as an independent prognostic factor for PFS and OS. Systematic LND may have therapeutic value in advanced EOC patients treated with NAC and IDS. ..

More Information


  1. Hornung M, Werner J, Schlitt H. Applications of hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Expert Rev Anticancer Ther. 2017;17:841-850 pubmed publisher
    ..Expert commentary: The CRS/HIPEC procedure represents a curative approach to treat patients with PC from CRC. However, surgical skills and the HIPEC technique still require specialized oncological centers. ..
  2. Falcone F, Scambia G, Benedetti Panici P, Signorelli M, Cormio G, Giorda G, et al. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study. Gynecol Oncol. 2017;147:66-72 pubmed publisher
    ..Accurate patient selection is of utmost importance to have the best chance of complete cytoreduction. ..
  3. Yang W, Cheng Z, Dai H, Long C, Liu H. Laparoscopic-based score assessment combined with a multiple disciplinary team in management of recurrent ovarian cancer: A single-center prospective study for personalized surgical therapy. Medicine (Baltimore). 2017;96:e7440 pubmed publisher
    ..5 vs 35.8?±?3.4 months, P?=?.027).Laparoscopic-based score assessment plus MDT helps to identify the appropriate patients to perform optimal secondary cytoreduction and provide a personalized surgical approach in management of ROC. ..
  4. Hall B, Padussis J, Foster J. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis. Surg Clin North Am. 2017;97:671-682 pubmed publisher
    ..It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer. ..
  5. Melamed A, Manning Geist B, Bregar A, Diver E, Goodman A, del Carmen M, et al. Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecol Oncol. 2017;147:250-256 pubmed publisher
    ..46, 95% CI=0.22-0.99). We found no evidence that surgical cytoreduction was of greater prognostic importance in high-grade serous carcinomas than in histologies that are less responsive to chemotherapy. ..
  6. Chandramohan A, Thrower A, Shah N, Mohamed F. Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. Br J Radiol. 2017;90:20170361 pubmed publisher
    ..To assess the imaging features of peritoneal mesothelioma and identify key anatomical sites that aid patient selection for complete cytoreduction...
  7. Gupta N, Asif S, Gandhi J, Rajpurohit S, Singh S. Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience. Indian J Gastroenterol. 2017;36:126-130 pubmed publisher
    ..In addition, it is associated with better overall survival. Morbidity profile of Indian subcontinent patients is different from that of western population with hematological toxicity being the most common. ..
  8. Altman A, McGee J, May T, Lane K, Lu L, Xu W, et al. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. Gynecol Oncol. 2017;147:257-261 pubmed publisher
    ..4cycles of NAC had a worse outcome than <3cycles likely due to poor prognostic factors or poor response. The number of consolidation cycles did not appear to make a difference in overall survival. ..
  9. Dell Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, et al. New surgical approaches for clinically high-risk or metastatic prostate cancer. Expert Rev Anticancer Ther. 2017;17:1013-1031 pubmed publisher
    ..In consequence, longer follow-up data and, ideally, randomized controlled trials are needed. ..
  10. van de Vrie R, van Meurs H, Rutten M, Naaktgeboren C, Opmeer B, Gaarenstroom K, et al. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. Gynecol Oncol. 2017;146:449-456 pubmed publisher
  11. . Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015;125:1006-26 pubmed publisher
  12. Li K, Mokdad A, Minter R, Mansour J, Choti M, Augustine M, et al. Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2017;214:209-215 pubmed publisher
    ..Therefore, ASA class 4 and dependent functional status should be considered as contraindications for CRS/HIPEC and only offered in highly selective cases. ..
  13. Magge D, Ramalingam L, Shuai Y, Edwards R, Pingpank J, Ahrendt S, et al. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer. J Surg Oncol. 2017;116:320-328 pubmed publisher
    ..However definite indications and timing of HIPEC need to be clarified by prospective studies. ..
  14. Gaujoux S, Mihai R. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg. 2017;104:358-376 pubmed publisher
    ..The present evidence-based recommendations provide comprehensive advice on the optimal perioperative care for patients undergoing surgery for ACC. ..
  15. Grimm C, Harter P, Alesina P, Prader S, Schneider S, Ataseven B, et al. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol. 2017;146:498-503 pubmed publisher
    ..2-3.4], p=0.01). In the present study, no predictive pre- and/or intraoperative risk factors for AL were identified. AL rate was mainly influenced by rectosigmoid resection and only marginally increased by additional bowel resections. ..
  16. Eriksson A, Graul A, Yu M, Halko A, Chi D, Zivanovic O, et al. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. Gynecol Oncol. 2017;146:263-267 pubmed publisher
    ..2% (SE 5.4%) MAS, 81.4% (SE 5.5%) LAP (P=0.7). MAS for SSCR is feasible in properly selected cases. MAS is associated with favorable perioperative outcomes and similar oncologic outcomes, compared to LAP. ..
  17. Phelps D, Borley J, Flower K, Dina R, Darb Esfahani S, Braicu I, et al. Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study. Br J Cancer. 2017;116:1287-1293 pubmed publisher
    ..46, 95% CI 0.21-1.01; P=0.05), and TCGA (HR 0.64, 95% CI 0.44-0.93; P=0.02)). MYLK3 methylation is associated with improved OS in patients with the least RD, which could potentially be used to determine response to surgery. ..
  18. Arians N, Kieser M, Benner L, Rochet N, Katayama S, Sterzing F, et al. Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study. Int J Radiat Oncol Biol Phys. 2017;99:912-920 pubmed publisher
  19. Han S, Sugarbaker P. Kocher maneuver to facilitate cytoreduction within the foramen of Winslow. J Surg Oncol. 2017;115:788-790 pubmed publisher
    ..In so doing, the foramen of Winslow is clearly exposed for peritonectomy. Residual tumor at this site is a prominent cause of unnecessary treatment failure in the management of patients with mucinous appendiceal neoplasms. ..
  20. Greco P, Bazzi A, McLean K, Reynolds R, Spencer R, Johnston C, et al. Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy. Obstet Gynecol. 2017;129:979-985 pubmed publisher
    ..Additional attention to venous thromboembolic prophylaxis during chemotherapy (neoadjuvant and adjuvant) in this patient population is warranted in an effort to decrease the rates of venous thromboembolism. ..
  21. Fader A, Bergstrom J, Jernigan A, Tanner E, Roche K, Stone R, et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. Gynecol Oncol. 2017;147:85-91 pubmed publisher
    ..A cooperative group, Phase III trial is planned to define the optimal therapy for women with this ovarian carcinoma subtype. ..
  22. Spencer R, Hacker K, Griggs J, Rice L, Reynolds R, Uppal S. Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery. Obstet Gynecol. 2017;130:305-314 pubmed publisher
    ..The 90-day mortality rate is double that of the 30-day rate and may be a better metric for assessing the initial quality of care for patients with ovarian cancer. ..
  23. Muallem M, Parashkevova A, Almuheimid J, Richter R, Diab Y, Braicu E, et al. Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer. Anticancer Res. 2017;37:3157-3161 pubmed
    ..Preoperative CA-125 is a poor, but statistically significant predictive factor for CTR after PCS. Preoperative CA-125 can predict neither the progression-free nor overall survival for POC patients. ..
  24. Park E, Baik S, Hur H, Min B, Kang J, Han Y, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colorectal cancer with peritoneal carcinomatosis: Clinical outcomes at 2 tertiary referral centers in Korea. Medicine (Baltimore). 2017;96:e6632 pubmed publisher
    ..All long-term complications, occurring in 10.6% of patients, were grades III-V.In this study, CRS with HIPEC was deemed feasible and safe for treating stage IV appendiceal or colorectal cancer with peritoneal carcinomatosis in Koreans. ..
  25. van Eden W, Kok N, Jozwiak K, Lahaye M, Beets G, van Leerdam M, et al. Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Dis Colon Rectum. 2017;60:477-487 pubmed publisher
    ..Timing of systemic chemotherapy does not appear to have impact on survival in patients with colorectal peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ..
  26. Takahashi A, Kato K, Matsuura M, Katsuda T, Matoda M, Nomura H, et al. Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients. Medicine (Baltimore). 2017;96:e8006 pubmed publisher
    ..02); however, overall survival did not differ (P?=?.23).SCS might be associated with improved PFS in ROC patients. SCS is beneficial in appropriately selected ROC patients. ..
  27. Bin Traiki T, Fisher O, Valle S, Parikh R, Kozman M, Glenn D, et al. Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:1939-1948 pubmed publisher
    ..Of these, about 1/3 may be eligible for PLAT. PLAT is a valuable treatment option providing good local control and potentially prolongation of overall survival. ..
  28. Dohan A, Barral M, Eveno C, Lo Dico R, Kaci R, Pasteur Rousseau A, et al. Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery. Eur J Surg Oncol. 2017;43:1932-1938 pubmed publisher
    ..827 [0.565-1.00]. Pre-operative BFV in the SMA correlates with extent and resectability of PMP. After incomplete surgery, post-operative BFV might aid in identifying patients who may benefit of post-operative therapy. ..
  29. Coleman R, Brady M, Herzog T, Sabbatini P, Armstrong D, Walker J, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779-791 pubmed publisher
    ..National Cancer Institute and Genentech. ..
  30. Morris R, Gani F, Hammad A, Peltier W, Gamblin T, Turaga K, et al. Factors associated with palliative care use in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2017;211:79-86 pubmed publisher
    ..Palliative care referrals were most commonly used for patients with chronic symptoms, which are difficult to manage, especially toward the end of life. ..
  31. Ly N, Wu L, Dalen R, Lolohea S. Short-term outcomes following cytoreductive surgery and heated intra-peritoneal chemotherapy at Waikato. N Z Med J. 2017;130:33-42 pubmed
    ..4%. The median hospital stay was 12 days. Short-term outcomes following CRS with IPC at Waikato are comparable to those published in the literature. Further follow-up is anticipated for the publication of survival and recurrence data. ..
  32. Khatib G, Güzel A, Gulec U, Vardar M. A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Çukurova technique). Gynecol Oncol. 2017;146:674-675 pubmed publisher
    ..We believe that this practical and effective technique will offer significant improvements in efforts to achieve complete cytoreduction. ..
  33. Liang P, Hu X. [Strategies of diagnosis and treatment for peritoneal metastasis of gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20:500-503 pubmed
    ..However, conversion therapy has been gradually incorporated into the treatment of peritoneal metastasis of gastric cancer because of the better efficacy and the higher survival. ..
  34. Hunsicker O, Feldheiser A, Weimann A, Liehre D, Sehouli J, Wernecke K, et al. Diagnostic value of plasma NGAL and intraoperative diuresis for AKI after major gynecological surgery in patients treated within an intraoperative goal-directed hemodynamic algorithm: A substudy of a randomized controlled trial. Medicine (Baltimore). 2017;96:e7357 pubmed publisher
    ..Intraoperative diuresis can be used to rule out AKI occurring up to 6?hours after surgery. ISRCTN 53154834. ..
  35. Jamieson A, Sykes P, Eva L, Bergzoll C, Simcock B. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence. Gynecol Oncol. 2017;146:273-278 pubmed publisher
  36. Greenwade M, Moore K, Gillen J, Ding K, Rowland M, Crim A, et al. Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017;146:465-469 pubmed publisher
    ..Increasing age was associated with non-participation. Modifiable barriers must be overcome so that trial enrollment can better reflect true EOC demographics. ..
  37. Lippitt M, Fairbairn M, Matsuno R, Stone R, Tanner E, Wick E, et al. Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer. Obstet Gynecol. 2017;130:756-764 pubmed publisher
    ..Implementation of a 5-point surgical site infection prevention bundle in women undergoing ovarian cancer operations was associated with dramatically decreased infection rates and lower hospital readmission rates. ..
  38. Mehta A, Bignell M, Alves S, Dayal S, Mohamed F, Cecil T, et al. Risk of Ovarian Involvement in Advanced Colorectal or Appendiceal Tumors Involving the Peritoneum. Dis Colon Rectum. 2017;60:691-696 pubmed publisher
    ..These results help to inform preoperative consent and intraoperative decision making in patients with advanced appendiceal and colorectal malignancy, and are of benefit in managing advanced lower GI tract malignancy. ..
  39. Szender J, Emmons T, Belliotti S, Dickson D, Khan A, Morrell K, et al. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol. 2017;146:491-497 pubmed publisher
    ..If these findings are confirmed in independent studies, consideration should be made to add the presence of large volume ascites at diagnosis to the staging criteria for ovarian cancer. ..